Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.42 |
| ▸ | CCND1 | P24385 | 4/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041525 | 0.91 | CDK4 (0.39) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL13553898 | 0.89 | CDK4 (0.41) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15785357 | 0.85 | TNK2 (0.41) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15036123 | 0.81 | CDK4 (0.43) | CDK4CCND1CCND2CCND3USP2 | |
| SCHEMBL13553764 | 0.79 | CDK4 (0.41) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15036063 | 0.78 | CDK4 (0.41) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15788014 | 0.77 | PAK4 (0.39) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15785232 | 0.76 | CDK4 (0.40) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL13553715 | 0.73 | CDK4 (0.41) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL15787984 | 0.72 | TYRO3 (0.44) | CDK4CCND1CCND2CCND3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | CDK4 460/4885CCND1 4243/4885CCND2 4217/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CCND2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.